Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed primary endometrial carcinoma meeting 1 of the following criteria: * Stage III or IV disease according to FIGO staging criteria * Recurrent disease that is considered incurable * Measurable disease * A lesion within a previously irradiated field is acceptable as measurable disease only if there has been clear progression since completion of radiotherapy PATIENT CHARACTERISTICS: * GOG performance status 0-2 * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 9 g/dL * Creatinine \< 2.5 mg/dL OR creatinine clearance ≥ 60 mL/min * ALT and AST ≤ 1.5 times upper limit of normal (ULN) (3 times ULN in the presence of liver metastases) * Alkaline phosphatase ≤ 1.5 times ULN (3 times ULN in the presence of liver metastases) * Total bilirubin ≤ 1.5 times ULN (3 times ULN in the presence of liver metastases) * Not pregnant or nursing * Left ventricular ejection fraction (LVEF) ≥ 50% by MUGA scan or ECHO * No history of severe hypersensitivity reaction to doxorubicin hydrochloride liposome * No other invasive malignancy (i.e., breast cancer) within the past 5 years except nonmelanoma skin cancer * No cardiac disease, including any of the following: * Myocardial infarction within the past 6 months * NYHA class II-IV heart failure * Uncontrolled angina * Severe uncontrolled ventricular arrhythmias * Clinically significant pericardial disease * Acute ischemic or active conduction system abnormalities by ECHO PRIOR CONCURRENT THERAPY: * No prior chemotherapy * No prior cancer therapy that would contraindicate study treatment * No concurrent investigational agents